AEON · AEON Biopharma Inc. Class A Common Stock
View on chartInsiders & Stakes
| Priveterra Sponsor, LLC 10% Owner | ▼ Sell | Other | 6,989,163 Shares held | 7/21/2023 | View profile |
| LYNCH TIMOTHY P | ▲ Buy | Open Market | 6,500,000 Shares held | 8/19/2026 | View profile |
| Bancroft Robert E. President & CEO | ▲ Buy | Grant | 3,177,103 Shares held | 2/17/2026 | View profile |
| Oh Chad CHIEF MEDICAL OFFICER | ▲ Buy | Grant | 2,183,436 Shares held | 3/4/2026 | View profile |
| Wilson Alexander Blair EXEC VP, CLO & CORP SECRETARY | ▲ Buy | Grant | 2,183,005 Shares held | 3/4/2026 | View profile |
| Strathspey Crown Holdings Group, LLC | ▼ Sell | Open Market | 2,031,773 Shares held | 8/11/2023 | View profile |
| Sy Jennifer PRINCIPAL ACCOUNTING OFFICER | ▲ Buy | Grant | 1,501,176 Shares held | 3/4/2026 | View profile |
| Forth Marc CHIEF EXECTUIVE OFFICER | ▲ Buy | Grant | 973,231 Shares held | 6/17/2026 | View profile |
| Bencich John CHIEF FINANCIAL OFFICER | ▲ Buy | Grant | 754,717 Shares held | 4/2/2026 | View profile |
| FISCHER JOST Director | ▲ Buy | Grant | 489,469 Shares held | 6/17/2026 | View profile |
| Robert J. Palmisano Director | ▲ Buy | Grant | 258,705 Shares held | 6/17/2026 | View profile |
| Shelley B. Thunen Chief Financial Officer | ▲ Buy | Grant | 258,705 Shares held | 6/17/2026 | View profile |
| Carter Eric G Director | ▲ Buy | Grant | 258,705 Shares held | 6/17/2026 | View profile |
Transaction History
| LYNCH TIMOTHY P | ▲ Buy | Open Market | 1,150,000 | $243K | 8/19/2026 |
| Carter Eric G | ▲ Buy | Grant | 222,684 | $0 | 6/17/2026 |
| FISCHER JOST | ▲ Buy | Grant | 222,684 | $0 | 6/17/2026 |
| Forth Marc | ▲ Buy | Grant | 222,684 | $0 | 6/17/2026 |
| Shelley B. Thunen | ▲ Buy | Grant | 222,684 | $0 | 6/17/2026 |
| Robert J. Palmisano | ▲ Buy | Grant | 222,684 | $0 | 6/17/2026 |
| Bencich John | ▲ Buy | Grant | 754,717 | $0 | 4/2/2026 |
| Oh Chad | ▲ Buy | Grant | 1,316,872 | $0 | 3/4/2026 |
| Wilson Alexander Blair | ▲ Buy | Grant | 1,316,872 | $0 | 3/4/2026 |
| Sy Jennifer | ▲ Buy | Grant | 925,925 | $0 | 3/4/2026 |
| Wilson Alexander Blair | ▲ Buy | Grant | 862,500 | $0 | 2/17/2026 |
| Oh Chad | ▲ Buy | Grant | 862,500 | $0 | 2/17/2026 |
| Sy Jennifer | ▲ Buy | Grant | 575,000 | $0 | 2/17/2026 |
| Bancroft Robert E. | ▲ Buy | Grant | 3,000,000 | $0 | 2/17/2026 |
| FISCHER JOST | ▲ Buy | Open Market | 60,000 | $29K | 5/21/2025 |
| FISCHER JOST | ▲ Buy | Open Market | 60,000 | $30K | 5/20/2025 |
| FISCHER JOST | ▲ Buy | Open Market | 50,000 | $25K | 5/19/2025 |
| Bancroft Robert E. | ▲ Buy | Grant | 177,103 | $0 | 5/14/2025 |
| Forth Marc | ▲ Buy | Grant | 470,692 | $0 | 8/31/2024 |
| Wilson Alexander Blair | ▲ Buy | Grant | 180,110 | $0 | 8/31/2024 |
| FISCHER JOST | ▲ Buy | Grant | 36,021 | $0 | 8/31/2024 |
| Oh Chad | ▲ Buy | Grant | 192,117 | $0 | 8/31/2024 |
| Sy Jennifer | ▲ Buy | Grant | 18,010 | $0 | 8/31/2024 |
| Carter Eric G | ▲ Buy | Grant | 36,021 | $0 | 8/31/2024 |
| Shelley B. Thunen | ▲ Buy | Grant | 36,021 | $0 | 8/31/2024 |
| Robert J. Palmisano | ▲ Buy | Grant | 36,021 | $0 | 8/31/2024 |
| Strathspey Crown Holdings Group, LLC | ▼ Sell | Open Market | 7,380,394 | $73.8M | 8/11/2023 |
| FISCHER JOST | ▲ Buy | Grant | 2,353 | — | 7/21/2023 |
| Priveterra Sponsor, LLC | ▼ Sell | Other | 89,163 | — | 7/21/2023 |
| FISCHER JOST | ▲ Buy | Grant | 13,274 | — | 7/21/2023 |
| Priveterra Sponsor, LLC | ▼ Sell | Other | 6,900,000 | — | 7/21/2023 |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 1, 2026
AEON Biopharma Shares FDA Feedback on ABP-450 Biosimilar Plan
AEON Biopharma received feedback from the FDA following a Type 2b meeting, which helps clarify the development path for its ABP-450 biosimilar candidate. This regulatory update provides specific guidance on the next steps for the company's pipeline. The stock recently appeared on lists of active healthcare names, reflecting market interest in this regulatory progress.
AEON Biopharma Shares FDA Feedback on ABP-450 Biosimilar Plan. AEON Biopharma received feedback from the FDA following a Type 2b meeting, which helps clarify the development path for its ABP-450 biosimilar candidate. This regulatory update provides specific guidance on the next steps for the company's pipeline. The stock recently appeared on lists of active healthcare names, reflecting market interest in this regulatory progress.